R&D channel feed

Rhythm says oral rare obe­si­ty drug clears Phase 2 test, plans tweaks to for­mu­la­tion

9 hours ago

As­traZeneca’s Alex­ion inks AAV cap­sid deal with JCR Phar­ma

10 hours ago
Cell/Gene Tx

'CRISPR Cures' cen­ter launch­es with $20M to make cus­tomized gene edit­ing ther­a­pies

Yesterday
Cell/Gene Tx

ProKid­ney's stock shoots high­er af­ter mixed Phase 2 da­ta

Yesterday

Ex­clu­sive: Start­up rais­es $45M for uni­ver­sal flu vac­cines made with mR­NA

Yesterday
Startups

Sin­ga­pore­an biotech gets Chi­na thumbs-up for study of po­ten­tial­ly cu­ra­tive HBV cell ther­a­py

Yesterday
China
Cell/Gene Tx

Clin­i­cian groups sue RFK Jr. and HHS over Covid-19 vac­cine rec­om­men­da­tion changes

2 days ago
Pharma
FDA+

Co­gent’s mas­to­cy­to­sis drug hits ‘home run’ in reg­is­tra­tional mid-stage tri­al

2 days ago

Com­pro­mised drug lot im­pacts Jasper's chron­ic hives study, stock falls

2 days ago
Manufacturing

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

2 days ago

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

6 days ago
Pharma

Struc­ture in part­ner­ing talks for GLP-1 pill as mid-stage read­out nears

6 days ago

4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans

6 days ago
People

Bris­tol My­er­s' Chi­na part­ner touts Phase 3 suc­cess for EGFRx­HER3 bis­pe­cif­ic ADC

Last week
China

Vyne stops en­rolling ear­ly-stage pso­ri­a­sis study fol­low­ing clin­i­cal hold lift, ear­ly da­ta

Last week

Ab­b­Vie cans oral ul­cer­a­tive col­i­tis drug from Lan­dos buy­out

Last week
Pharma

Sh­iono­gi, BioVer­sys team up on an­tibi­otics for lung dis­ease in deal worth up to $614M

Last week
Deals

PBM re­forms fail to make the cut as Sen­ate pass­es Trump’s mega­bill

Last week
Pharma
FDA+

Ad­vo­cates urge J&J to ‘put every­thing on the ta­ble’ for gene ther­a­py de­spite failed tri­al

Last week
Cell/Gene Tx
In Focus

Beck­ley touts pos­i­tive mid-stage psy­che­del­ic da­ta fol­low­ing atai merg­er plans

Last week

Pro­tag­o­nist un­veils 'triple-G' obe­si­ty pill, but hu­man tri­als are near­ly a year away

Last week

Pfiz­er ends Phase 1b/2 tri­al for fi­nal Tril­li­um CD47 drug

Last week

Arc­turus claims Phase 2 suc­cess in first da­ta since shift to mR­NA ther­a­peu­tics, in­vestor re­ac­tion is mut­ed

Last week

CBER chief Prasad sug­gests Covid vac­cine harms may out­weigh ben­e­fits in 'low-risk pop­u­la­tion­s'

Last week
Pharma
FDA+
1234 Next page Last page
A service from the Financial Times